Target intelligence / Profile preview

Latent membrane protein 1-derived peptide-human leukocyte antigen class I complex (LMP1-peptide-HLA class I complex)

Target
LMP1-peptide-HLA class I complex
Molecular classification
Other
01

Overview

The latent membrane protein 1 (LMP1)-derived peptide-human leukocyte antigen (HLA) class I complex is a peptide-major histocompatibility complex (pMHC) class I assembly presented on the surface of cells infected with Epstein-Barr virus (EBV). LMP1 is a key viral oncogene consistently expressed in EBV-associated malignancies, such as nasopharyngeal carcinoma (NPC), Hodgkin's lymphoma, and post-transplant lymphoproliferative disorders (PTLD). Intracellular processing of LMP1 generates specific antigenic peptides (such as YLLEMLWRL or YLQQNWWTL) that are loaded onto HLA class I molecules (most commonly HLA-A*02:01) and presented on the cell surface. This complex serves as a critical target for the host's adaptive immune system, specifically recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes (CTLs). In therapeutic development, the LMP1-peptide-HLA class I complex is targeted using novel immunotherapies to treat EBV-positive cancers. These therapies include TCR-engineered T-cell (TCR-T) therapies (such as YT-E001), TCR-like monoclonal antibodies (such as L1), and chimeric antigen receptor (CAR) T-cell therapies designed to recognize the specific pMHC complex. Additionally, adoptive cell therapies utilizing EBV-specific T cells (such as tabelecleucel) exploit this target to selectively eliminate EBV-infected tumor cells. However, targeting this complex faces challenges, including antigen escape through LMP1 sequence mutations or HLA downregulation, and potential safety concerns like cytokine release syndrome or off-target toxicity due to cross-reactivity with self-peptides.

Other names
LMP1-derived peptide-HLA class I complexLMP1-peptide-MHC class I complexHLA-A*02:01-restricted LMP1 peptide complexHLA-A2-restricted LMP1 peptide complexLMP1-derived peptide-HLA-A*02:01 complexLMP1-derived peptide-HLA-A2 complexLatent membrane protein 1-derived peptide-MHC class I complex
02

Mechanism of action

Targeted cell lysis via T-cell receptor (TCR) or chimeric antigen receptor (CAR) binding to the peptide-HLA complex, triggering cytotoxic T-lymphocyte (CTL) activation and immune-mediated destruction of EBV-infected cells.

03

Biological functions

Immune responseAntigen presentationOther
04

Disease associations

CancerInfectionOther
05

Safety considerations

On-target, off-tumor toxicity due to cross-reactivity with self-peptides (molecular mimicry)Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)Antigen escape via LMP1 mutations or downregulationHLA downregulation or loss of heterozygosity (LOH)Allogeneic rejection of off-the-shelf cellular therapies
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

HLA-A*02:01 expressionHLA-A2 expressionLMP1 expressionEpstein-Barr virus (EBV) positivityEBER (EBV-encoded RNA) positivity

Beyond the preview

Go deeper on Latent membrane protein 1-derived peptide-human leukocyte antigen class I complex (LMP1-peptide-HLA class I complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latent membrane protein 1-derived peptide-human leukocyte antigen class I complex (LMP1-peptide-HLA class I complex).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call